In the burgeoning RNAi sector, a handful of companies are working to develop the technology into a source of human therapeutics. Only one — Sirna Therapeutics — has said that it expects to have an RNAi drug ready for clinical trials next year.

But now, a Philadelphia-based start-up is pushing into the foreground with a seasoned biotech player in front and a even more ambitious timeline than its bigger rival.